[CAS NO. 1346452-25-2] Enfortumab vedotin-ejfv
PRODUCTS SPECIFICATIONS [1346452-25-2]
DESCRIPTION [1346452-25-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Enfortumab vedotin-ejfv] |
Summary
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma [1] .
In Vitro
Enfortumab vedotin-ejfv is a fully human IgG1-kappa antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable maleimidocaproyl valine-citrulline linker (SGD-1006) [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04724018 | Dana-Farber Cancer Institute|Gilead Sciences |
Urothelial Cancer|Metastatic Urothelial Carcinoma|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Bladder Cancer
|
May 20, 2021 | Phase 1 |
| NCT04887870 | Mirati Therapeutics Inc. |
Advanced or Metastatic Solid Malignancies
|
June 30, 2021 | Phase 2|Phase 3 |
Appearance
Solid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021 Jun;55(6):772-782.
- [2] Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Feb 15;27(4):922-927.
